In recent years, rare disease treatment has rapidly risen from a niche medical issue to one of the most active core areas of global pharmaceutical

In recent years, immune checkpoint inhibitors have revolutionized the field of anti-tumor treatment, among which PD-1 (programmed death protein 1) monoclonal antibodies have become a

In the field of tenosynovial giant cell tumor (TGCT), a rare but persistent disease that impairs joint function, long-term systemic treatment options are limited. The

In the treatment of leukemia, not all patients respond equally to standard therapies. Drug resistance and genetic mutations can significantly reduce the effectiveness of commonly

Multiple myeloma is a chronic and often relapsing hematologic malignancy that requires long-term, repeated treatment. Over the past decade, therapeutic advances—particularly the introduction of monoclonal

Biologic therapies have fundamentally changed how chronic inflammatory diseases are treated, shifting the focus from broad immunosuppression to targeted immune modulation. From this evolving therapeutic

What is Taltz ixekizumab used for? This is a common question among patients and healthcare professionals seeking clearer information about modern biologic therapies for immune-mediated